JW1601

Small moleculeexperimental

Clinical trial activity

7 trials · 10 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
5
Phase 3
0
Phase 4
0

Earliest trial started Aug 10, 2015 (NCT02538471)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2019

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06644040Phase 1Oct 25, 2024QuadMedicine
NCT06363552Phase 2May 31, 2024Fudan University
NCT06055348Phase 1/Phase 2 (Phase 2)Oct 30, 2023Biocity Biopharmaceutics Co., Ltd.
NCT05682170Phase 1/Phase 2 (Phase 2)Dec 1, 2022K-Group Beta, Zentalis Pharmaceuticals
NCT05543681Phase 2Oct 11, 2022IGC Pharma LLC
NCT04018170Phase 1Feb 15, 2019JW Pharmaceutical, Yonsei University
NCT02538471Phase 2Aug 10, 2015Cornell University, University of California, Los Angeles
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (10)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Biocity Biopharmaceutics Co., Ltd.For profit1112023
Cornell UniversityAcademic/Hospital1112015
Fudan UniversityAcademic/Hospital1112024
IGC Pharma LLCFor profit1112022
JW PharmaceuticalFor profit1112019
K-Group BetaFor profit1012022
QuadMedicineFor profit1112024
University of California, Los AngelesAcademic/Hospital1012015
Yonsei UniversityAcademic/Hospital1012019
Zentalis PharmaceuticalsFor profit1112022
10 organizations
Page 1 / 1